• linkedin
  • Increase Font
  • Sharebar

    Role of blue light cystoscopy to detect bladder cancer

    Increased tumor detection, reduced recurrence/progression support its use in NMIBC patients


    Decreased tumor recurrence, progression

    The improved detection of tumors with BLC has demonstrated a resultant improvement in tumor recurrence. Meta-analyses have shown a 12% to 31% improvement in 12-month recurrence-free survival rates (Eur Urol 2013; 64:846-54; PLoS ONE 2013; 8:e74142). Improvements in progression rates are less clear-cut than those of recurrence rates. This may be due to two factors. First, there is a lack of consistency in the definition of “progression” among trials. Second, most trials are powered to detect changes in recurrence, not progression.

    However, despite these limitations, BLC does appear to impact progression, albeit to a lesser degree than recurrence. In one randomized phase III trial, progression to muscle-invasive disease does not appear to be impacted
    (J Urol 2012; 188:58-62). However, progression in grade and/or stage within the NMIBC disease state is improved by 5% (Bladder Cancer 2016; 2:273-8). Further, a meta-analysis revealed a 4% improvement in progression rates, but was limited by different definitions of progression among the included studies (Bladder Cancer 2016; 2:293-300).

    Adoption of technique/application

    While BLC represents a technique that many urologists may not have learned during their initial training, in the simplest of explanations it is merely a WLC with some changes in the colors visualized. While this is a minor difference, it does require a slight learning curve. A single-center study evaluating interobserver agreement found that 20 and 30 cases were required for good and excellent agreement, respectively (Can J Urol 2012; 19:6269-73).

    This learning curve may vary from center to center depending on frequency of the technique’s use, with higher volume centers likely to see a shorter learning curve. This improvement is probably most important to avoid false positives from the increased fluorescence of benign inflammatory lesions.

    Read: Immediate post-TURBT mitomycin instillation reduces recurrence risk

    Further considerations when initially implementing BLC into one’s practice are those of its logistical and financial impact. BLC does require preoperative intravesical instillation of HAL with a dwell time of approximately 1 hour prior to the procedure. This may impact the workflow of some practice settings. However, in these authors’ experience, this implementation can be streamlined with minimal impact on workflow with appropriate education of the entire treatment team.

    Regarding cost, an upfront investment in appropriate equipment is required to perform BLC. In the United States, the KARL STORZ D-Light C Photodynamic Diagnostic System is linked to the FDA’s approval of HAL. While the capital costs of this system may seem significant, BLC has been shown to carry a lower cost burden overall ($5,000 less over 5 years) given the lower cancer burden (Can J Urol 2013; 20:6682–9).


    BLC is an adjunctive technique that should be considered for all patients with bladder cancer, particularly at the time of initial TURBT. Its increased tumor detection and resultant reduction in tumor recurrence and progression support its use as a cost-effective and successful method for decreasing overall tumor burden in NMIBC patients.

    For these reasons, the use of BLC is recommended by the AUA/SUO as well as these authors.

    More from Urology Times:

    Cost considerations in the management of bladder cancer

    Test could help detect bladder cancer recurrence

    How will immunotherapy change the future of bladder Ca care?

    Subscribe to Urology Times to get monthly news from the leading news source for urologists.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available